483 related articles for article (PubMed ID: 29065820)
1. Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.
Viola-Rhenals M; Patel KR; Jaimes-Santamaria L; Wu G; Liu J; Dou QP
Curr Med Chem; 2018 Feb; 25(4):506-524. PubMed ID: 29065820
[TBL] [Abstract][Full Text] [Related]
2. Disulfiram's Anticancer Activity: Evidence and Mechanisms.
Jiao Y; Hannafon BN; Ding WQ
Anticancer Agents Med Chem; 2016; 16(11):1378-1384. PubMed ID: 27141876
[TBL] [Abstract][Full Text] [Related]
3. Differential Cytotoxicity Mechanisms of Copper Complexed with Disulfiram in Oral Cancer Cells.
Chen SY; Chang YL; Liu ST; Chen GS; Lee SP; Huang SM
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918312
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity.
Hasinoff BB; Patel D
Arch Biochem Biophys; 2017 Nov; 633():23-28. PubMed ID: 28887129
[TBL] [Abstract][Full Text] [Related]
5. Novel Disulfiram Derivatives as ALDH1a1-Selective Inhibitors.
Omran Z
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056791
[TBL] [Abstract][Full Text] [Related]
6. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
7. Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase.
Skrott Z; Majera D; Gursky J; Buchtova T; Hajduch M; Mistrik M; Bartek J
Oncogene; 2019 Oct; 38(40):6711-6722. PubMed ID: 31391554
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme - A propos of a case.
Karamanakos PN; Trafalis DT; Papachristou DJ; Panteli ES; Papavasilopoulou M; Karatzas A; Kardamakis D; Nasioulas G; Marselos M
J BUON; 2017; 22(5):1227-1232. PubMed ID: 29135106
[TBL] [Abstract][Full Text] [Related]
9. Dual Action of Acidic Microenvironment on the Enrichment of the Active Metabolite of Disulfiram in Tumor Tissues.
Tang C; Pang X; Guo Z; Guo R; Liu L; Chen X
Drug Metab Dispos; 2021 Jun; 49(6):434-441. PubMed ID: 33762296
[TBL] [Abstract][Full Text] [Related]
10. The combination of disulfiram and copper for cancer treatment.
Li H; Wang J; Wu C; Wang L; Chen ZS; Cui W
Drug Discov Today; 2020 Jun; 25(6):1099-1108. PubMed ID: 32320854
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram: a novel repurposed drug for cancer therapy.
Lu C; Li X; Ren Y; Zhang X
Cancer Chemother Pharmacol; 2021 Feb; 87(2):159-172. PubMed ID: 33426580
[TBL] [Abstract][Full Text] [Related]
12. Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents.
Ekinci E; Rohondia S; Khan R; Dou QP
Recent Pat Anticancer Drug Discov; 2019; 14(2):113-132. PubMed ID: 31084595
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line.
Butcher K; Kannappan V; Kilari RS; Morris MR; McConville C; Armesilla AL; Wang W
BMC Cancer; 2018 Jul; 18(1):753. PubMed ID: 30031402
[TBL] [Abstract][Full Text] [Related]
14. Repurposing Disulfiram as a Chemo-Therapeutic Sensitizer: Molecular Targets and Mechanisms.
Sun F; Wang H; Nie J; Hong B
Anticancer Agents Med Chem; 2022; 22(17):2920-2926. PubMed ID: 35430981
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
[TBL] [Abstract][Full Text] [Related]
16. Advantages and disadvantages of disulfiram coadministered with popular addictive substances.
Kleczkowska P; Sulejczak D; Zaremba M
Eur J Pharmacol; 2021 Aug; 904():174143. PubMed ID: 33971180
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
[TBL] [Abstract][Full Text] [Related]
18. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B; Dvorak Z
Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.
Kannappan V; Ali M; Small B; Rajendran G; Elzhenni S; Taj H; Wang W; Dou QP
Front Mol Biosci; 2021; 8():741316. PubMed ID: 34604310
[TBL] [Abstract][Full Text] [Related]
20. An Updated Review of Disulfiram: Molecular Targets and Strategies for Cancer Treatment.
Yang Q; Yao Y; Li K; Jiao L; Zhu J; Ni C; Li M; Dou QP; Yang H
Curr Pharm Des; 2019; 25(30):3248-3256. PubMed ID: 31419930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
